MedTrace Logo

Decipher Lethal Prostate Cancer Biology - Urine Metabolomics

NCT03237702 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2026-01-20

No results posted yet for this study

Summary

Through a better understanding of the biology of significant (lethal) prostate cancer, we hope to develop new markers/targets from urine metabolomics for more effective screening and prevention of significant prostate cancer. In the meantime, with these new markers we may substantially reduce overtreatment of insignificant PC.

Conditions

  • Significant Prostate Cancer

Interventions

DIETARY_SUPPLEMENT

Multi-Carotenoids

All participants in the second stage will receive multi-carotenoids 30 mg qd for 8 weeks.

Sponsors & Collaborators

  • Taipei Medical University Hospital

    collaborator OTHER

  • Taipei Veterans General Hospital, Taiwan

    collaborator OTHER_GOV

  • Cardinal Tien Hospital

    collaborator OTHER

  • Taipei Medical University Shuang Ho Hospital

    collaborator OTHER

  • Far Eastern Memorial Hospital

    collaborator OTHER

  • Taichung Tzu Chi Hospital

    collaborator OTHER

  • Shin Kong Wu Ho-Su Memorial Hospital

    collaborator OTHER

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Yeong-Shiau Pu, MD PhD · Department of Urology, National Taiwan University Hospital

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2027-08-01
Completion
2027-08-01

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03237702 on ClinicalTrials.gov